NO179124C - Fremgangsmåte for fremstilling av et injiserbart, vandig, farmasöytisk preparat av 3-(hydroksymetyl)-5,5-difenylhydantoin-dinatriumfosfatester - Google Patents
Fremgangsmåte for fremstilling av et injiserbart, vandig, farmasöytisk preparat av 3-(hydroksymetyl)-5,5-difenylhydantoin-dinatriumfosfatesterInfo
- Publication number
- NO179124C NO179124C NO914582A NO914582A NO179124C NO 179124 C NO179124 C NO 179124C NO 914582 A NO914582 A NO 914582A NO 914582 A NO914582 A NO 914582A NO 179124 C NO179124 C NO 179124C
- Authority
- NO
- Norway
- Prior art keywords
- hydroxymethyl
- pharmaceutical composition
- phosphate ester
- disodium phosphate
- diphenylhydantoin
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- -1 3- (hydroxymethyl) -5,5-diphenylhydantoin disodium phosphate ester Chemical class 0.000 title 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 abstract 3
- 230000015556 catabolic process Effects 0.000 abstract 3
- 238000006731 degradation reaction Methods 0.000 abstract 3
- 229960002036 phenytoin Drugs 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- MUTSJHVOFFHGGL-UHFFFAOYSA-N 2-(n-phenylanilino)acetamide Chemical compound C=1C=CC=CC=1N(CC(=O)N)C1=CC=CC=C1 MUTSJHVOFFHGGL-UHFFFAOYSA-N 0.000 abstract 1
- 230000002920 convulsive effect Effects 0.000 abstract 1
- 239000008380 degradant Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Dental Preparations (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/356,948 US4925860A (en) | 1987-08-05 | 1989-05-25 | Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester |
| PCT/US1990/002733 WO1990014080A1 (en) | 1989-05-25 | 1990-05-24 | Stable pharmaceutical composition of 3-(hydroxymethyl)-5,5-diphenylhydantoin disodium phosphate ester |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| NO914582D0 NO914582D0 (no) | 1991-11-22 |
| NO914582L NO914582L (no) | 1991-11-22 |
| NO179124B NO179124B (no) | 1996-05-06 |
| NO179124C true NO179124C (no) | 1996-08-14 |
Family
ID=23403641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO914582A NO179124C (no) | 1989-05-25 | 1991-11-22 | Fremgangsmåte for fremstilling av et injiserbart, vandig, farmasöytisk preparat av 3-(hydroksymetyl)-5,5-difenylhydantoin-dinatriumfosfatester |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US4925860A (da) |
| EP (1) | EP0473687B1 (da) |
| JP (1) | JP3143471B2 (da) |
| KR (1) | KR0143768B1 (da) |
| AT (1) | ATE135907T1 (da) |
| AU (1) | AU632130B2 (da) |
| CA (1) | CA2067122A1 (da) |
| CZ (1) | CZ277918B6 (da) |
| DE (2) | DE69026253T2 (da) |
| DK (1) | DK0473687T3 (da) |
| ES (1) | ES2086404T3 (da) |
| FI (1) | FI101041B (da) |
| HU (1) | HU212944B (da) |
| IE (1) | IE81130B1 (da) |
| IL (1) | IL94504A (da) |
| LU (1) | LU90340I2 (da) |
| MX (1) | MX9203584A (da) |
| MY (1) | MY106190A (da) |
| NL (1) | NL980045I2 (da) |
| NO (1) | NO179124C (da) |
| NZ (1) | NZ233808A (da) |
| PT (1) | PT94161B (da) |
| RU (1) | RU2075973C1 (da) |
| SG (1) | SG64881A1 (da) |
| SK (1) | SK277911B6 (da) |
| WO (1) | WO1990014080A1 (da) |
| ZA (1) | ZA904038B (da) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU624262B2 (en) * | 1989-08-10 | 1992-06-04 | Warner-Lambert Company | Use of prophenytoin for treating stroke |
| SI0900227T1 (en) | 1996-04-30 | 2002-04-30 | Warner-Lambert Company | Improved process for the synthesis of diesters of phosphoric acid 2,5-dioxo-4,4-diphenyl-imidazolidin-1-ylmethyl ester |
| US6133248A (en) * | 1997-06-13 | 2000-10-17 | Cydex, Inc. | Polar drug of prodrug compositions with extended shelf-life storage and a method of making thereof |
| AU8479998A (en) * | 1997-07-22 | 1999-02-16 | Warner-Lambert Company | Lyophilized fosphenytoin sodium for parenteral use |
| US6110499A (en) * | 1997-07-24 | 2000-08-29 | Alza Corporation | Phenytoin therapy |
| AU2985100A (en) | 1999-02-08 | 2000-08-25 | Checkpoint Genetics, Inc. | (n)-substituted amino acids, antioxidant pharmaceutical compositions containing same and methods using same |
| AU5824800A (en) * | 1999-06-23 | 2001-01-31 | Warner-Lambert Company | Use of fosphenytoin for the treatment of acute neuropathic pain |
| US20060034910A1 (en) * | 2004-08-09 | 2006-02-16 | Sanjay Patel | Pharmaceutical composition for extended release of phenytoin sodium |
| US20070244074A1 (en) * | 2006-04-17 | 2007-10-18 | Sougata Pramanick | Stable parenteral formulation of fosphenytoin sodium |
| KR101303088B1 (ko) * | 2009-02-17 | 2013-09-06 | 한림제약(주) | 3-(히드록시메틸)-5,5-디페닐히단토인 이나트륨 포스페이트에스테르를 함유하는 주사용 약학 조성물 |
| CA2937222C (en) | 2009-06-25 | 2019-06-04 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| US8431576B2 (en) | 2009-06-25 | 2013-04-30 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| ES2691671T3 (es) | 2010-06-24 | 2018-11-28 | Alkermes Pharma Ireland Limited | Profármacos de compuestos NH-acídicos: derivados de éster, carbonato, carbamato y fosfonato |
| HUE065359T2 (hu) | 2011-03-18 | 2024-05-28 | Alkermes Pharma Ireland Ltd | Szorbitán-észtereket tartalmazó gyógyászati készítmények |
| UY34072A (es) | 2011-05-17 | 2013-01-03 | Novartis Ag | Derivados sustituidos de indol |
| JP5952912B2 (ja) | 2011-12-15 | 2016-07-13 | アルカーメス ファーマ アイルランド リミテッド | 二級アミン化合物のプロドラッグ |
| JP6219918B2 (ja) | 2012-03-19 | 2017-10-25 | アルカームス ファーマ アイルランド リミテッド | グリセロールエステルを含む医薬組成物 |
| ES2765036T3 (es) | 2012-03-19 | 2020-06-05 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden esteres de ácidos grasos |
| ES2950418T3 (es) | 2012-03-19 | 2023-10-09 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden alcohol bencílico |
| EP2897592B1 (en) | 2012-09-19 | 2020-02-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| CN103288877B (zh) * | 2013-05-10 | 2016-03-09 | 安徽省先锋制药有限公司 | 磷苯妥英稳定的有机胺盐及其制备方法和用途 |
| BR112016021535A8 (pt) | 2014-03-20 | 2021-07-20 | Alkermes Pharma Ireland Ltd | kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso |
| EP3761983A1 (en) | 2018-03-05 | 2021-01-13 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| AU2020480182B2 (en) | 2020-12-04 | 2025-02-27 | Sichuan Credit Pharmaceutical Co., Ltd | Fosphenytoin sodium solid composition, lyophilization method, and use of fosphenytoin sodium solid composition |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4260769A (en) * | 1977-04-22 | 1981-04-07 | Interx Research Corporation | 5,5-Diphenylhydantoins |
-
1989
- 1989-05-25 US US07/356,948 patent/US4925860A/en not_active Expired - Lifetime
-
1990
- 1990-05-24 WO PCT/US1990/002733 patent/WO1990014080A1/en not_active Ceased
- 1990-05-24 JP JP02508239A patent/JP3143471B2/ja not_active Expired - Lifetime
- 1990-05-24 AT AT90908752T patent/ATE135907T1/de active
- 1990-05-24 SG SG1996003778A patent/SG64881A1/en unknown
- 1990-05-24 DE DE69026253T patent/DE69026253T2/de not_active Expired - Lifetime
- 1990-05-24 IE IE187290A patent/IE81130B1/en not_active IP Right Cessation
- 1990-05-24 AU AU56704/90A patent/AU632130B2/en not_active Expired
- 1990-05-24 ES ES90908752T patent/ES2086404T3/es not_active Expired - Lifetime
- 1990-05-24 MY MYPI90000848A patent/MY106190A/en unknown
- 1990-05-24 DE DE1999175021 patent/DE19975021I2/de active Active
- 1990-05-24 CA CA002067122A patent/CA2067122A1/en not_active Abandoned
- 1990-05-24 NZ NZ233808A patent/NZ233808A/en unknown
- 1990-05-24 KR KR1019910701660A patent/KR0143768B1/ko not_active Expired - Lifetime
- 1990-05-24 RU SU905010404A patent/RU2075973C1/ru active
- 1990-05-24 HU HU905265A patent/HU212944B/hu unknown
- 1990-05-24 DK DK90908752.0T patent/DK0473687T3/da active
- 1990-05-24 EP EP90908752A patent/EP0473687B1/en not_active Expired - Lifetime
- 1990-05-25 CZ CS902566A patent/CZ277918B6/cs not_active IP Right Cessation
- 1990-05-25 ZA ZA904038A patent/ZA904038B/xx unknown
- 1990-05-25 IL IL9450490A patent/IL94504A/en not_active IP Right Cessation
- 1990-05-25 SK SK2566-90A patent/SK277911B6/sk not_active IP Right Cessation
- 1990-05-25 PT PT94161A patent/PT94161B/pt not_active IP Right Cessation
-
1991
- 1991-11-21 FI FI915491A patent/FI101041B/fi active Protection Beyond IP Right Term
- 1991-11-22 NO NO914582A patent/NO179124C/no not_active IP Right Cessation
-
1992
- 1992-06-26 MX MX9203584A patent/MX9203584A/es active IP Right Grant
-
1998
- 1998-12-24 NL NL980045C patent/NL980045I2/nl unknown
-
1999
- 1999-01-19 LU LU90340C patent/LU90340I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO179124C (no) | Fremgangsmåte for fremstilling av et injiserbart, vandig, farmasöytisk preparat av 3-(hydroksymetyl)-5,5-difenylhydantoin-dinatriumfosfatester | |
| ES2122076T3 (es) | Derivados de nor-acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos. | |
| BR9204577A (pt) | Processo para obtencao de uma formulacao de liberacao controlada estabilizada,produto estabilizado e forma de dosagem solida de liberacao controlada estabilizada | |
| GB8819110D0 (en) | Antihypertensive drug & method for production | |
| PT99597B (pt) | Processo para a preparacao de derivados do acido hidroxamico que inibem a lipoxigenase | |
| PT99402A (pt) | Processo para a preparacao de derivados de imino ciclicos e de composicoes farmaceuticas que os contem | |
| LV12189A (lv) | Panemiens N-amino-1-hidroksialkiliden-1,1-bifosfon-skabju iegusanai | |
| ATE149826T1 (de) | Verfahren zur herstellung von festen pharmazeutischen retardformen | |
| ES2143132T3 (es) | Monohidratos de derivado de acido aminobenceno-sulfonico y su metodo de preparacion. | |
| NO177845C (no) | Fremgangsmåte for fremstilling av et preparat for öyedråper | |
| ES2113040T3 (es) | Procedimiento de un solo recipiente para la fabricacion de derivados del acido 3-quinoloncarboxilico. | |
| ES2127302T3 (es) | Composiciones farmaceuticas que incluyen polimeros en silicato. | |
| IT1236843B (it) | Processo per la preparazione di 4-0-fosfati di dopamina o suoi derivati | |
| NO303715B1 (no) | Stabilt, vandig apparat | |
| ATE70055T1 (de) | Verfahren zur hestellung halogenierter hydantoine. | |
| PT90362A (pt) | Metodo para o tratamento de doencas muco-epiteliais e da pele em mamiferos que utiliza acidos 4-quinolinocarboxilicos e seus derivados e processo para a preparacao de composicoes farmaceuticas que contem os mesmos compostos | |
| SE9300758L (sv) | Förfarande för framställning av kavulansyrasalter | |
| BE893492A (fr) | Procede de preparation d'esters d'acides apovincaminiques, esters ainsi obtenus et compositions pharmaceutiques prepares avec ces esters | |
| ATE99946T1 (de) | Lagerstabile orale glucosaminsulfat-dosisformen und verfahren zu deren herstellung. | |
| SE8303399D0 (sv) | Azo-bis-salicyl syra och salt derav, deras farmaceutiska beredning samt framstellning av syran | |
| BR0013563A (pt) | Preparação farmacêutica sólida, utilização de uma preparação farmacêutica e processo para a produção de uma preparação farmacêutica | |
| GR1001133B (el) | Μέ?οδος παρασκευής στα?ερής σύν?εσης δινατρίου άλατος φωσφορικού εστέρος 3-(υδροξυμε?υλο)-5,5-διφαινυλουδαντοϊνης. | |
| AR002736A1 (es) | Uso de ester 3-metil-5-etilico de acido 2,6-dimetil-4-(2,3-diclorofenil-1,4 -dihidropiridin-3,5-dicarboxilico (felodipina) para fabricar un medicamento ypreparacion farmaceutica para el tratamiento de la disfuncion cerebral. | |
| IT7869219A0 (it) | Acidi fenil alconoici sostituiti e loro derivati particolarmente utili nella preparazione dei medicamenti e procedimento per la loro preparazione | |
| IT8821189A0 (it) | Di estere fosforico dell'acido ursodeossicolico e suoi derivati, processo per la loro preparazione e composizioni terapeutiche che li contengono come principi attivi. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |